Intravesical instillation with epirubicin as a prophylactic treatment for superficial bladder cancer - Using two different schedules

Naoki Segawa, Takeshi Nishida, Kiyoshi Takahara, Hayahito Nomi, Haruhito Azuma, Yoji Katsuoka

研究成果: Article

2 引用 (Scopus)

抄録

Intravesical chemotherapy is performed after transurethral resection of bladder tumor (TURBT) for superficial bladder cancer. We conducted a prospective randomized controlled study on the prophylactic effects of intravesical instillation of epirubicin (EPI) against recurrence to determine the effective administration schedule. Between April 1999 and March 2003, 54 patients with superficial bladder tumor (pTa or pTl, and G1 or G2 cancer) were assigned to two groups (25 in Group A, 29 in Group B) after TURBT. The schedule of instillation (intravesically 40 mg of EPI dissolved in 40 ml saline) was subsequently once every two weeks for 3 months (7 times) starting one week after TURBT (Group A, short period), and subsequently added every two weeks for 3 months starting 6 months after TURBT (Group B, long period). The patients were followed up by cystoscopy and urinary cytology. There was no significant difference in non-recurrence rates after either one year (A; 62.5%, B; 82.8%) or three years (A; 53.6%, B; 67.3%). A univariate analysis demonstrated that tumor grade and staging were significant predictors of high risk for recurrence. A multivariate analysis performed by using the Cox's proportional hazard model showed that the schedule of instillation was an independent prognostic factor for reccurence. In the present study, only 2 patients showed progression and one patient died of UC. There was no adverse event that forced discontinuation of the therapy. In conclusion, epirubicin instillation influenced the prevention of recurrence, but the benefit of long-term period was not confirmed.

元の言語English
ページ(範囲)711-716
ページ数6
ジャーナルActa Urologica Japonica
54
発行部数11
出版物ステータスPublished - 01-11-2008
外部発表Yes

Fingerprint

Intravesical Administration
Epirubicin
Urinary Bladder Neoplasms
Appointments and Schedules
Recurrence
Therapeutics
Cystoscopy
Neoplasm Staging
Proportional Hazards Models
Cell Biology
Multivariate Analysis
Drug Therapy
Neoplasms

All Science Journal Classification (ASJC) codes

  • Urology

これを引用

Segawa, Naoki ; Nishida, Takeshi ; Takahara, Kiyoshi ; Nomi, Hayahito ; Azuma, Haruhito ; Katsuoka, Yoji. / Intravesical instillation with epirubicin as a prophylactic treatment for superficial bladder cancer - Using two different schedules. :: Acta Urologica Japonica. 2008 ; 巻 54, 番号 11. pp. 711-716.
@article{69a9ffcf68204374b63394bdd5fcf552,
title = "Intravesical instillation with epirubicin as a prophylactic treatment for superficial bladder cancer - Using two different schedules",
abstract = "Intravesical chemotherapy is performed after transurethral resection of bladder tumor (TURBT) for superficial bladder cancer. We conducted a prospective randomized controlled study on the prophylactic effects of intravesical instillation of epirubicin (EPI) against recurrence to determine the effective administration schedule. Between April 1999 and March 2003, 54 patients with superficial bladder tumor (pTa or pTl, and G1 or G2 cancer) were assigned to two groups (25 in Group A, 29 in Group B) after TURBT. The schedule of instillation (intravesically 40 mg of EPI dissolved in 40 ml saline) was subsequently once every two weeks for 3 months (7 times) starting one week after TURBT (Group A, short period), and subsequently added every two weeks for 3 months starting 6 months after TURBT (Group B, long period). The patients were followed up by cystoscopy and urinary cytology. There was no significant difference in non-recurrence rates after either one year (A; 62.5{\%}, B; 82.8{\%}) or three years (A; 53.6{\%}, B; 67.3{\%}). A univariate analysis demonstrated that tumor grade and staging were significant predictors of high risk for recurrence. A multivariate analysis performed by using the Cox's proportional hazard model showed that the schedule of instillation was an independent prognostic factor for reccurence. In the present study, only 2 patients showed progression and one patient died of UC. There was no adverse event that forced discontinuation of the therapy. In conclusion, epirubicin instillation influenced the prevention of recurrence, but the benefit of long-term period was not confirmed.",
author = "Naoki Segawa and Takeshi Nishida and Kiyoshi Takahara and Hayahito Nomi and Haruhito Azuma and Yoji Katsuoka",
year = "2008",
month = "11",
day = "1",
language = "English",
volume = "54",
pages = "711--716",
journal = "Acta Urologica Japonica",
issn = "0018-1994",
publisher = "Editorial Board of Acta Urologica Japonica",
number = "11",

}

Intravesical instillation with epirubicin as a prophylactic treatment for superficial bladder cancer - Using two different schedules. / Segawa, Naoki; Nishida, Takeshi; Takahara, Kiyoshi; Nomi, Hayahito; Azuma, Haruhito; Katsuoka, Yoji.

:: Acta Urologica Japonica, 巻 54, 番号 11, 01.11.2008, p. 711-716.

研究成果: Article

TY - JOUR

T1 - Intravesical instillation with epirubicin as a prophylactic treatment for superficial bladder cancer - Using two different schedules

AU - Segawa, Naoki

AU - Nishida, Takeshi

AU - Takahara, Kiyoshi

AU - Nomi, Hayahito

AU - Azuma, Haruhito

AU - Katsuoka, Yoji

PY - 2008/11/1

Y1 - 2008/11/1

N2 - Intravesical chemotherapy is performed after transurethral resection of bladder tumor (TURBT) for superficial bladder cancer. We conducted a prospective randomized controlled study on the prophylactic effects of intravesical instillation of epirubicin (EPI) against recurrence to determine the effective administration schedule. Between April 1999 and March 2003, 54 patients with superficial bladder tumor (pTa or pTl, and G1 or G2 cancer) were assigned to two groups (25 in Group A, 29 in Group B) after TURBT. The schedule of instillation (intravesically 40 mg of EPI dissolved in 40 ml saline) was subsequently once every two weeks for 3 months (7 times) starting one week after TURBT (Group A, short period), and subsequently added every two weeks for 3 months starting 6 months after TURBT (Group B, long period). The patients were followed up by cystoscopy and urinary cytology. There was no significant difference in non-recurrence rates after either one year (A; 62.5%, B; 82.8%) or three years (A; 53.6%, B; 67.3%). A univariate analysis demonstrated that tumor grade and staging were significant predictors of high risk for recurrence. A multivariate analysis performed by using the Cox's proportional hazard model showed that the schedule of instillation was an independent prognostic factor for reccurence. In the present study, only 2 patients showed progression and one patient died of UC. There was no adverse event that forced discontinuation of the therapy. In conclusion, epirubicin instillation influenced the prevention of recurrence, but the benefit of long-term period was not confirmed.

AB - Intravesical chemotherapy is performed after transurethral resection of bladder tumor (TURBT) for superficial bladder cancer. We conducted a prospective randomized controlled study on the prophylactic effects of intravesical instillation of epirubicin (EPI) against recurrence to determine the effective administration schedule. Between April 1999 and March 2003, 54 patients with superficial bladder tumor (pTa or pTl, and G1 or G2 cancer) were assigned to two groups (25 in Group A, 29 in Group B) after TURBT. The schedule of instillation (intravesically 40 mg of EPI dissolved in 40 ml saline) was subsequently once every two weeks for 3 months (7 times) starting one week after TURBT (Group A, short period), and subsequently added every two weeks for 3 months starting 6 months after TURBT (Group B, long period). The patients were followed up by cystoscopy and urinary cytology. There was no significant difference in non-recurrence rates after either one year (A; 62.5%, B; 82.8%) or three years (A; 53.6%, B; 67.3%). A univariate analysis demonstrated that tumor grade and staging were significant predictors of high risk for recurrence. A multivariate analysis performed by using the Cox's proportional hazard model showed that the schedule of instillation was an independent prognostic factor for reccurence. In the present study, only 2 patients showed progression and one patient died of UC. There was no adverse event that forced discontinuation of the therapy. In conclusion, epirubicin instillation influenced the prevention of recurrence, but the benefit of long-term period was not confirmed.

UR - http://www.scopus.com/inward/record.url?scp=57449110993&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=57449110993&partnerID=8YFLogxK

M3 - Article

VL - 54

SP - 711

EP - 716

JO - Acta Urologica Japonica

JF - Acta Urologica Japonica

SN - 0018-1994

IS - 11

ER -